Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Single-Center Study of MTG201 in Combination With Nivolumab in Patients With Relapsed Malignant Pleural Mesothelioma

NCT04013334 is registered in ClinicalTrials.gov with Momotaro-Gene Inc. as lead sponsor.

NCT NCT04013334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04013334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Single-Center Study of MTG201 in Combination With Nivolumab in Patients With Relapsed Malignant Pleural Mesothelioma
Lead sponsor
Momotaro-Gene Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
August 15, 2019
Completion date
January 1, 2023
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant pleural mesothelioma